The significance is the people running the trial got the enrichment right a while ago, after, I think, the first DMC report and the estimate then, after enrichment was the MACE needed to reach the primary endpoint would be around late 2019.
The enrichment was to add more placebo stage 3 CHF patients, because based on estimates then, at the first DMC announcement, the trial would not complete in a reasonable time.
I'm pretty happy with mid December 2019.
Ann: CHF P3 Trial Accrues Sufficient Primary Endpoint Events, page-15
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
-0.068(5.38%) |
Mkt cap ! $1.367B | |||
| Open | High | Low | Value | Volume |
| $1.22 | $1.23 | $1.18 | $5.355M | 4.464M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 102816 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 64368 | 35 |
View Market Depth
| Last trade - 13.29pm 25/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |